GLP-1 Therapy & Cardiometabolic Health

The World Health Organization guidelines for use of GLP-1 medicines in treating obesity and patients with type 2 diabetes.

Printable summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults    

Clinical recommendations and expert consensus on managing GI adverse events in patients on GLP-1s.

A practical framework from Obesity Canada to support structured, patient-centred conversations and management of obesity in clinical practice.

Resources from Obesity Canada on pharmacological approaches to obesity management and their role alongside lifestyle interventions.

Learn about weight bias and its impact on people living with obesity and type 2 diabetes, and support more respectful, person-centred care; from Obesity Canada

Cleveland Clinic provides GLP-1 diet guidance , what foods to choose, what food to limit or avoid, and how to plan meals on GLP-1 therapies.

A literature review (2025) exploring the future of lifestyle prioritization in patients on GLP-1 therapies. 

Explore research by the American Heart Association (2025) that focuses on healthy lifestyle combined with newer diabetes medications lowered cardiovascular risk

This research article looks at the important role of nutrition, physical activity and other health behaviours in holistic type 2 diabetes management while taking GLP-1s

JAMA Internal Medicine Patient Page explores the topic of "I Am Taking a GLP-1 Weight-Loss Medication - What Should I Know?"